Figure 1. HLH was more refractory and... | American Society of Hematology

Figure 1.

$HLH was more refractory and more active at the time of HSCT in patients receiving emapalumab. (A) The number of salvage therapies used before HSCT, including emapalumab as a salvage agent. Use of salvage therapy was significantly higher in the emapalumab cohort (P < .0001). A persistent but less striking difference was noted when emapalumab was not included as a salvage agent (P = .0059). (B) Number of HLH-2004 criteria met including recent imaging with splenomegaly and laboratory-based criteria obtained within 2 weeks before starting the preparative regimen. (C) Significant preconditioning laboratory markers. Salvage therapies were treated as continuous variables based on the number of agents used. Individual laboratory markers were also treated as continuous variables and both analyses were performed with the Mann-Whitney U test. Total HLH-2004 criteria met was grouped as those meeting 0 to 4 criteria vs ≥5 criteria and compared via the Fisher exact test. Additional details on salvage therapies, sCD25 trends, and nonsignificant HLH-2004 markers are shown in supplemental Figure 3. ∗∗∗∗P < .0001; ∗∗P < .01; ∗P < .05.$

HLH was more refractory and more active at the time of HSCT in patients receiving emapalumab. (A) The number of salvage therapies used before HSCT, including emapalumab as a salvage agent. Use of salvage therapy was significantly higher in the emapalumab cohort (P < .0001). A persistent but less striking difference was noted when emapalumab was not included as a salvage agent (P = .0059). (B) Number of HLH-2004 criteria met including recent imaging with splenomegaly and laboratory-based criteria obtained within 2 weeks before starting the preparative regimen. (C) Significant preconditioning laboratory markers. Salvage therapies were treated as continuous variables based on the number of agents used. Individual laboratory markers were also treated as continuous variables and both analyses were performed with the Mann-Whitney U test. Total HLH-2004 criteria met was grouped as those meeting 0 to 4 criteria vs ≥5 criteria and compared via the Fisher exact test. Additional details on salvage therapies, sCD25 trends, and nonsignificant HLH-2004 markers are shown in supplemental Figure 3. ∗∗∗∗P < .0001; ∗∗P < .01; ∗P < .05.

This Feature Is Available To Subscribers Only